Gossamer Bio, Inc. (NASDAQ:GOSS) Given Consensus Rating of “Hold” by Brokerages

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have earned a consensus rating of “Hold” from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $6.6667.

A number of research firms have recently commented on GOSS. Wedbush reaffirmed a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Gossamer Bio in a research report on Tuesday, February 24th. Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a report on Friday, January 23rd. Barclays cut shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a report on Tuesday, February 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Gossamer Bio in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group cut shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. MMA Asset Management LLC bought a new stake in Gossamer Bio in the 4th quarter valued at approximately $31,000. Soltis Investment Advisors LLC bought a new stake in shares of Gossamer Bio in the fourth quarter worth $31,000. Ciovacco Capital Management LLC acquired a new position in Gossamer Bio during the third quarter worth $27,000. Beacon Pointe Advisors LLC acquired a new position in Gossamer Bio during the fourth quarter worth $34,000. Finally, Ieq Capital LLC bought a new position in Gossamer Bio in the fourth quarter valued at $35,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Stock Performance

GOSS opened at $0.47 on Wednesday. Gossamer Bio has a 52 week low of $0.33 and a 52 week high of $3.87. The company has a fifty day moving average price of $2.29 and a two-hundred day moving average price of $2.61. The firm has a market capitalization of $108.79 million, a PE ratio of -0.68 and a beta of 2.08.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.